Greenwood Capital Associates LLC grew its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 89.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 164,023 shares of the company’s stock after purchasing an additional 77,380 shares during the quarter. Greenwood Capital Associates LLC’s holdings in TherapeuticsMD were worth $1,076,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. raised its holdings in TherapeuticsMD by 84.4% in the 1st quarter. Principal Financial Group Inc. now owns 59,178 shares of the company’s stock worth $288,000 after purchasing an additional 27,081 shares in the last quarter. Fox Run Management L.L.C. bought a new position in TherapeuticsMD in the second quarter worth about $121,000. Dupont Capital Management Corp bought a new position in TherapeuticsMD in the second quarter worth about $352,000. Raymond James Financial Services Advisors Inc. raised its holdings in TherapeuticsMD by 18.6% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 213,522 shares of the company’s stock worth $1,332,000 after purchasing an additional 33,480 shares in the last quarter. Finally, TD Asset Management Inc. raised its holdings in TherapeuticsMD by 24.7% in the second quarter. TD Asset Management Inc. now owns 427,602 shares of the company’s stock worth $2,668,000 after purchasing an additional 84,700 shares in the last quarter. 67.56% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have commented on TXMD. BidaskClub upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday. Oppenheimer set a $14.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, November 7th. Cantor Fitzgerald set a $27.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, November 2nd. Finally, ValuEngine downgraded shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Monday, October 29th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. TherapeuticsMD currently has a consensus rating of “Buy” and a consensus target price of $13.45.
TXMD opened at $4.91 on Monday. TherapeuticsMD Inc has a 52-week low of $4.30 and a 52-week high of $7.66. The company has a debt-to-equity ratio of 0.55, a quick ratio of 7.15 and a current ratio of 7.23. The stock has a market cap of $1.17 billion, a PE ratio of -13.27 and a beta of 1.40.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.06. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The firm had revenue of $3.47 million for the quarter, compared to the consensus estimate of $4.43 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company’s revenue for the quarter was down 21.5% compared to the same quarter last year. On average, analysts anticipate that TherapeuticsMD Inc will post -0.59 earnings per share for the current fiscal year.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
See Also: Short Selling Stocks and Day Traders
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.